MKI67
MKI67 encodes Ki-67, a widely used nuclear marker of cellular proliferation.
MKI67 encodes Ki-67, a widely used nuclear marker of cellular proliferation. In biomedical research and pathology, Ki-67 is commonly assessed by immunohistochemistry to estimate the proportion of cells actively cycling, making it a practical indicator of tissue growth, regeneration, and hyperproliferative states. Because its expression is associated with proliferating cells rather than quiescent cells, MKI67 is frequently used as a readout of biological activity in normal development, injury, and disease.
Functionally, Ki-67 is most often interpreted as a proliferation-associated protein rather than a direct therapeutic target. In experimental settings, changes in Ki-67 staining can help characterize whether a treatment preserves, restores, or suppresses tissue cell turnover. It is often evaluated alongside markers of apoptosis and stress responses, such as BCL2 apoptosis regulator (Bcl-2) family proteins or proinflammatory cytokine-related pathways, to provide a broader picture of tissue injury and recovery.
Where the papers sit
11 papers from the last 6 months study MKI67 directly · updated from PubMed 8 Oct 2026
Study type 1 clinical trial · 5 observational · 1 human data · 2 preclinical · 2 unclassified
Themes 3 themes · 1 new direction
-
Breast Cancer Response Biomarkers
Ki67 is moving beyond a proliferation readout toward a biomarker of endocrine response, pathological complete response and invasive disease-free survival in breast cancer. The strongest clinical focus is HER2-positive and hormone-receptor-positive disease, including short preoperative endocrine therapy. Mechanistic work connects Ki67 with circulating tumour-cell intravasation and metastasis, while CD47 and KLF4 mark related metastatic biology. Prospective validation and treatment-specific thresholds remain open questions.
4 papers · 36.4%
-
Imaging-Based Ki67 Prediction
Noninvasive imaging is being developed to estimate Ki67 expression before tissue sampling in glioma and hepatocellular carcinoma. ConvNeXt-Tiny models combine imaging with IDH prediction in glioma, while T2-weighted MRI habitat analysis supports Ki67 prediction in liver tumours. The direction is toward quantitative, preoperative molecular profiling rather than biopsy-only assessment. Dual-center validation is encouraging, but broader external validation and clinical utility remain unresolved.
2 papers · 18.2%
-
Others — Cross-Disease Molecular Markers
SIRT6, BAX, inflammatory cytokines and Ki67 appear across studies of toxic injury, solid tumours, lymphoma and tissue pathology. The work links these markers to apoptosis, enhancer activity, proliferation and treatment response. Findings remain disease-specific, with no shared mechanism or therapeutic direction. The cluster is best viewed as a collection of molecular marker studies rather than one developing research programme.
5 papers · 45.5%
Ki-67 functions as a driver of metastatic competence independently of proliferation
Breast cancer mouse models with circulating tumor cells were assumed to use Ki-67 primarily as a marker of proliferation, but CRISPR screens showed that Ki-67 knockout reduced CTC intravasation and metastasis without suppressing proliferation; instead, Ki-67 maintained cell-cell-adhesion genes including CD47 and KLF4. This places MKI67 outside its marker role as a regulator of collective invasion and metastatic dissemination 42139058May.
Papers
The 11 papers from the last 6 months that study MKI67 directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Breast Cancer Response Biomarkers (4)
- Ki-67 promotes circulating tumor cell intravasation and metastasis in breast cancer. Cell reports · 15 May 2026 PMID 42139058
- The predictive role of Ki67 in pathological complete response (pCR) and invasive disease-free survival (IDFS) in HER2-positive breast cancer: a bi-centric retrospective cohort study of 244 cases. Archives of gynecology and obstetrics · 2 May 2026 PMID 42068346
- New Pathological Insights into Biomarkers for Multimodal Therapeutic Approach in Hepatic Neuroendocrine Tumors: A Detailed Case Report. In vivo (Athens, Greece) · 28 Apr 2026 PMID 42049452
- Clinical and molecular biomarkers for prediction of endocrine response after short preoperative endocrine therapy in the WSG ADAPT-HR+/HER2- and ADAPTcycle trials (N = 7914). Annals of oncology : official journal of the European Society for Medical Oncology · 18 Apr 2026 PMID 41999978
Imaging-Based Ki67 Prediction (2)
- A multimodal ConvNeXt-Tiny deep learning model for simultaneous prediction of IDH mutation and Ki-67 expression in gliomas. PloS one · 26 Jun 2026 PMID 42361071
- Prediction of Ki-67 expression in hepatocellular carcinoma: a dual-center study based on T2-weighted imaging habitat analysis. Radiology and oncology · 26 Jun 2026 PMID 42359754
Others — Cross-Disease Molecular Markers (5)
- Protective effects of Withania somnifera (Ashwagandha) against chronic unpredictable mild stress-induced testicular damage in adolescent rats. Journal of molecular histology · 18 Jun 2026 PMID 42315798
- High intrapancreatic fat deposition accelerates pancreatic ductal adenocarcinoma growth and metastasis with enrollment of FABP5 upregulation. Scientific reports · 6 Jun 2026 PMID 42251134
- Comparison of dose-adjusted EPOCH-R and R-CHOP in diffuse large B-cell lymphoma with high Ki67 expression: Results from a prospective observational study. PloS one · 22 May 2026 PMID 42172280
- Integrating network toxicology with multi-omics approaches to elucidate molecular targets and pathway mechanisms in BPA-induced hepatocellular carcinoma. Molecular diversity · 12 May 2026 PMID 42118483
- Onychopapilloma Is a Nail Bed Onycholemmal Papilloma: A Clinical and Histological Study of 56 Cases, Including Seborrheic Keratosis-Like Lesions. The American Journal of dermatopathology · 21 Apr 2026 PMID 42012242
By study type
Clinical trials (1)
- Clinical and molecular biomarkers for prediction of endocrine response after short preoperative endocrine therapy in the WSG ADAPT-HR+/HER2- and ADAPTcycle trials (N = 7914). Annals of oncology : official journal of the European Society for Medical Oncology · 18 Apr 2026 PMID 41999978
Observational studies and case reports (5)
- A multimodal ConvNeXt-Tiny deep learning model for simultaneous prediction of IDH mutation and Ki-67 expression in gliomas. PloS one · 26 Jun 2026 PMID 42361071
- Prediction of Ki-67 expression in hepatocellular carcinoma: a dual-center study based on T2-weighted imaging habitat analysis. Radiology and oncology · 26 Jun 2026 PMID 42359754
- Comparison of dose-adjusted EPOCH-R and R-CHOP in diffuse large B-cell lymphoma with high Ki67 expression: Results from a prospective observational study. PloS one · 22 May 2026 PMID 42172280
- The predictive role of Ki67 in pathological complete response (pCR) and invasive disease-free survival (IDFS) in HER2-positive breast cancer: a bi-centric retrospective cohort study of 244 cases. Archives of gynecology and obstetrics · 2 May 2026 PMID 42068346
- New Pathological Insights into Biomarkers for Multimodal Therapeutic Approach in Hepatic Neuroendocrine Tumors: A Detailed Case Report. In vivo (Athens, Greece) · 28 Apr 2026 PMID 42049452
Human data, design not indexed (1)
- Onychopapilloma Is a Nail Bed Onycholemmal Papilloma: A Clinical and Histological Study of 56 Cases, Including Seborrheic Keratosis-Like Lesions. The American Journal of dermatopathology · 21 Apr 2026 PMID 42012242
Preclinical: animal, cell and lab studies (2)
- Protective effects of Withania somnifera (Ashwagandha) against chronic unpredictable mild stress-induced testicular damage in adolescent rats. Journal of molecular histology · 18 Jun 2026 PMID 42315798
- Ki-67 promotes circulating tumor cell intravasation and metastasis in breast cancer. Cell reports · 15 May 2026 PMID 42139058
Unclassified: not yet indexed with MeSH (2)
- High intrapancreatic fat deposition accelerates pancreatic ductal adenocarcinoma growth and metastasis with enrollment of FABP5 upregulation. Scientific reports · 6 Jun 2026 PMID 42251134
- Integrating network toxicology with multi-omics approaches to elucidate molecular targets and pathway mechanisms in BPA-induced hepatocellular carcinoma. Molecular diversity · 12 May 2026 PMID 42118483
Written from 11 PubMed abstracts, each one listed by PMID above. Published: 2026-07-02. Last written: 2026-08-26 by GPT. Drafted by language models from published abstracts; not medical advice.